




>>Entry Name: Fulvestrant, BAN, INN

Synonym(s): 7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol, 9Cl. Faslodex. ICI 182780



Molecular Formula: C₃₂H₄₇F₅O₃S

Molecular Weight: 606.78

Accurate Mass: 606.316605

Percentage Composition: C 63.34%; H 7.81%; F 15.66%; O 7.91%; S 5.28%

Biological Use/Importance: Antiestrogen. Used in the treatment of breast cancer

Physical Description: No phys. props. accessible

>>Variant: (7 α ,17 β)-form

CAS Registry Number: 129453-61-8

Molecular Formula: C₃₂H₄₇F₅O₃S

Molecular Weight: 606.78

Accurate Mass: 606.316605

Percentage Composition: C 63.34%; H 7.81%; F 15.66%; O 7.91%; S 5.28%

Physical Description: Solid

Melting Point: Mp 102-104°

Optical Rotation: [α]_D²²+13 (c, 0.52 in CHCl₃)

References:

Wakeling, A.E. *et al.*, *Cancer Res.*, 1991, **51**, 3867-3873, (*pharmacol*)

Dukes, M. *et al.*, *J. Endocrinol.*, 1992, **135**, 239-247, (*pharmacol*)

Wade, G.N., *Am. J. Physiol.*, 1993, **265**, R1392, (*rev*)

Ger. Pat., 1993, *Schering*, 4 218 743; *CA*, **120**, 134927n, (*synth*)

Nicholson, R.I. *et al.*, *Ann. N.Y. Acad. Sci.*, 1995, **761**, 148, (*rev*)

Howell, A. *et al.*, *Br. J. Cancer*, 1996, **74**, 300-308, (*pharmacol, pharmacokinet*)

McClelland, R.A. *et al.*, *Eur. J. Cancer, Part A*, 1996, **32**, 413-416, (*pharmacol*)

England, G.M. *et al.*, *Oncol. Res.*, 1997, **9**, 397, (*rev*)

Curran, M. *et al.*, *Drugs*, 2001, **61**, 807-813, (*rev*)